Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male/female subjects 12 years of age and older~2. Provide written informed consent/pediatric assent.~3. Subjects must have moderate-to-severe rhinitis, with one or more of the following present:~   1. Sleep disturbance~  2. Impairment of daily activities, leisure and/or sport~  3. Impairment of school or work~  4. Troublesome symptoms~4. Screening Visit: Have a 12-hour reflective TNSS of at least 8 out of a possible 12 and a congestion score of 2 or 3 on Visit 1~5. Randomization Visit: For the 3 days prior to Randomization and on the morning of Randomization, the sum of the 7 consecutive reflective AM and PM TNSS assessments shall be equal to or greater than 56, with a nasal congestion score equal to or greater than 14~6. Randomization Visit: instantaneous TNSS score of at least 8 and a congestion score of at least 2 just prior to beginning the onset of action assessment~7. Have taken at least 10 doses of the lead-in medication~8. Willing and able to comply with the study requirements~9. At least a 2-year history of SAR during the current allergy season~10. The presence of IgE-mediated hypersensitivity to a prevailing, individual, seasonal pollen, confirmed by a positive response to skin prick within the last year.~11. General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results.~12. Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit~13. Subjects currently receiving sublingual immunotherapy are excluded. A 6-month washout period is required following the last dose of sublingual immunotherapy.~Exclusion Criteria:~1. On Focused Nasal Examination, the presence of any superficial and moderate nasal mucosal erosion, nasal mucosal ulceration, or nasal septum perforation (Grade 1b - 4) at either the screening visit or randomization visit will disqualify the subject from the study.~2. Other nasal disease(s) likely to affect deposition of intranasal medication.~3. Nasal surgery or sinus surgery within the previous year.~4. Chronic sinusitis - more than 3 episodes per year~5. Planned travel outside of the pollen area during the study period~6. The use of any investigational drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study~7. Presence of any hypersensitivity to drugs similar to azelastine hydrochloride or fluticasone propionate~8. Women who are pregnant or nursing~9. Women of childbearing potential who are not abstinent or not practicing a medically acceptable method of contraception\* see section 6.1.1~10. Respiratory Tract Infections within 14 days prior to Visit 1~11. Respiratory Tract Infections requiring antibiotic treatment 14 days prior to Visit 1~12. Asthma (with the exception of intermittent asthma).~13. Significant pulmonary disease including COPD~14. Clinically significant arrhythmia or symptomatic cardiac conditions~15. A known history of alcohol or drug abuse within the last 2 years~16. Existence of any surgical or medical condition or physical or laboratory findings, might significantly alter the absorption, distribution, metabolism, or excretion of study drug; that might significantly affect the subject's ability to complete this trial; or their safety in this trial.~17. Patients with a history of glaucoma~18. Clinically relevant abnormal physical findings within 1 week of randomization may preclude compliance with the study procedures~19. Employees of the research center or private practice and their family members~20. no more than 50% of their subjects have participated in protocol MP4001, MP4002 or MP4004

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): None
- azelastine Hcl (Type: ACTIVE_COMPARATOR): None
- fluticasone propionate (Type: ACTIVE_COMPARATOR): None
- azelastine Hcl /fluticasone propionate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).